Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karen Lam

Showing results (1-10 of 38) with videos related to

Pageof 4
Sort By:
Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics|January 13, 2004
The effect of Emdogain gel on periodontal healing in replanted monkeys' teethKaren Lam, Varawan Sae-Lim
Mabs|November 5, 2016
Development and preclinical studies of <sup>64</sup>Cu-NOTA-pertuzumab F(ab')<sub>2</sub> for imaging changes in tumor HER2 expression associated with response to trastuzumab by PET/CTKaren Lam, Conrad Chan, Raymond M Reilly
Nuclear Medicine and Biology|November 11, 2019
Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [<sup>111</sup>In]In-Bn-DTPA-nimotuzumab in mice with triple-negative or trastuzumab-resistant human breast cancer xenografts that overexpress EGFRConrad Chan, Humphrey Fonge, Karen Lam, et al.
Bioconjugate Chemistry|March 18, 2015
Advancing novel molecular imaging agents from preclinical studies to first-in-humans phase I clinical trials in academia--a roadmap for overcoming perceived barriersRaymond M Reilly, Karen Lam, Conrad Chan, et al.
Skin Health and Disease|December 3, 2024
Expanding subcutaneous mass on the scalp of an immunocompromised womanIvan Rodriguez, Karen Lam, Simone Montgomery, et al.
Case Reports in Dermatology|June 4, 2024
Eruptive Melanocytic Nevi in the Setting of Encorafenib, Cetuximab, and Binimetinib Combination Therapy: A Case ReportKaren Lam, Gregory A Gates, Daniel Q Bach, et al.
Molecular Pharmaceutics|June 30, 2018
Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with <sup>89</sup>Zr-Labeled Trastuzumab-DM1: A Comparison with <sup>89</sup>Zr-Labeled TrastuzumabNoor Al-Saden, Karen Lam, Conrad Chan, et al.
Journal of Neurophysiology|March 22, 2013
Serotonergic modulation of neuronal activity in rat midbrain periaqueductal grayHyo-Jin Jeong, Karen Lam, Vanessa A Mitchell, et al.
Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine|December 3, 2014
Kit for the preparation of <sup>111</sup>In-labeled pertuzumab injection for imaging response of HER2-positive breast cancer to trastuzumab (Herceptin)Karen Lam, Deborah A Scollard, Conrad Chan, et al.
Nuclear Medicine and Biology|December 3, 2014
Preclinical pharmacokinetics, biodistribution, radiation dosimetry and acute toxicity studies required for regulatory approval of a Clinical Trial Application for a Phase I/II clinical trial of (111)In-BzDTPA-pertuzumabKaren Lam, Conrad Chan, Susan J Done, et al.
Pageof 4

Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics|January 13, 2004
The effect of Emdogain gel on periodontal healing in replanted monkeys' teethKaren Lam, Varawan Sae-Lim
Mabs|November 5, 2016
Development and preclinical studies of <sup>64</sup>Cu-NOTA-pertuzumab F(ab')<sub>2</sub> for imaging changes in tumor HER2 expression associated with response to trastuzumab by PET/CTKaren Lam, Conrad Chan, Raymond M Reilly
Nuclear Medicine and Biology|November 11, 2019
Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [<sup>111</sup>In]In-Bn-DTPA-nimotuzumab in mice with triple-negative or trastuzumab-resistant human breast cancer xenografts that overexpress EGFRConrad Chan, Humphrey Fonge, Karen Lam, et al.
Bioconjugate Chemistry|March 18, 2015
Advancing novel molecular imaging agents from preclinical studies to first-in-humans phase I clinical trials in academia--a roadmap for overcoming perceived barriersRaymond M Reilly, Karen Lam, Conrad Chan, et al.
Skin Health and Disease|December 3, 2024
Expanding subcutaneous mass on the scalp of an immunocompromised womanIvan Rodriguez, Karen Lam, Simone Montgomery, et al.
Case Reports in Dermatology|June 4, 2024
Eruptive Melanocytic Nevi in the Setting of Encorafenib, Cetuximab, and Binimetinib Combination Therapy: A Case ReportKaren Lam, Gregory A Gates, Daniel Q Bach, et al.
Molecular Pharmaceutics|June 30, 2018
Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with <sup>89</sup>Zr-Labeled Trastuzumab-DM1: A Comparison with <sup>89</sup>Zr-Labeled TrastuzumabNoor Al-Saden, Karen Lam, Conrad Chan, et al.
Journal of Neurophysiology|March 22, 2013
Serotonergic modulation of neuronal activity in rat midbrain periaqueductal grayHyo-Jin Jeong, Karen Lam, Vanessa A Mitchell, et al.
Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine|December 3, 2014
Kit for the preparation of <sup>111</sup>In-labeled pertuzumab injection for imaging response of HER2-positive breast cancer to trastuzumab (Herceptin)Karen Lam, Deborah A Scollard, Conrad Chan, et al.
Nuclear Medicine and Biology|December 3, 2014
Preclinical pharmacokinetics, biodistribution, radiation dosimetry and acute toxicity studies required for regulatory approval of a Clinical Trial Application for a Phase I/II clinical trial of (111)In-BzDTPA-pertuzumabKaren Lam, Conrad Chan, Susan J Done, et al.
Pageof 4